Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.
Morningstar brands and products Company Portfolio ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback